Key Points
-
Fibroblast growth factor (FGF) signalling controls a myriad of processes in embryonic development and in tissue homeostasis and metabolism in the adult. Recent structural studies have provided a glimpse of the complexity of molecular control that is in place to fine-tune this signalling system to enable it to produce specific signalling outputs in diverse biological contexts.
-
The interaction of FGFs with heparan sulphate glycosaminoglycan chains of heparan sulphate proteoglycans in the pericellular and extracellular matrix defines their mode of action, that is, whether an FGF acts in a paracrine or endocrine fashion. It also determines the shape of gradient formed by a paracrine FGF ligand in the extracellular matrix, which in turn is a determinant of the biological response to that ligand.
-
In addition to mechanisms common to all FGFs, such as the interaction with heparan sulphate, the biological activity of individual ligands or ligand subfamilies is regulated by mechanisms unique to these ligands: amino-terminal alternative splicing controls the activity of FGF8 subfamily ligands; homodimerization autoinhibits the activity of FGF9 subfamily ligands; and site-specific proteolytic cleavage inactivates the phosphaturic hormone FGF23.
-
Alternative splicing in the extracellular immunoglobulin-like domain 3 (D3) of FGF receptor 1 (FGFR1), FGFR2 and FGFR3 primarily determines the ligand-binding specificity of these receptors. This splicing event is fundamental to the establishment of directional paracrine FGF signalling between the epithelium and the mesenchyme, which underlies the coordinated cellular processes that govern organ development.
-
Klotho co-receptors convert FGFRs into specific receptors for endocrine FGFs by a dual mechanism; these co-receptors not only enhance the binding affinity of FGFRs for endocrine FGFs but concomitantly suppress the binding of paracrine FGFs to FGFRs. The finding that heparan sulphate is dispensable for signalling by endocrine FGFs implies that Klotho co-receptors also promote FGFR dimerization upon endocrine FGF binding, which is required for FGFR activation.
-
The structural findings suggest that there may be no functional redundancy among FGF ligands, and genetic data support this conclusion. Hence, future studies should concentrate on identifying novel ligand-specific functions of FGF signalling.
Abstract
Fibroblast growth factors (FGFs) mediate a broad range of functions in both the developing and adult organism. The accumulated wealth of structural information on the FGF signalling pathway has begun to unveil the underlying molecular mechanisms that modulate this system to generate a myriad of distinct biological outputs in development, tissue homeostasis and metabolism. At the ligand and receptor level, these mechanisms include alternative splicing of the ligand (FGF8 subfamily) and the receptor (FGFR1–FGFR3), ligand homodimerization (FGF9 subfamily), site-specific proteolytic cleavage of the ligand (FGF23), and interaction of the ligand and the receptor with heparan sulphate cofactor and Klotho co-receptor.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Itoh, N. & Ornitz, D. M. Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J. Biochem. 149, 121–130 (2011).
Mohammadi, M., Olsen, S. K. & Ibrahimi, O. A. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev. 16, 107–137 (2005).
Itoh, N. & Ornitz, D. M. Evolution of the Fgf and Fgfr gene families. Trends Genet. 20, 563–569 (2004).
Schlessinger, J. et al. Crystal structure of a ternary FGF–FGFR–heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol. Cell 6, 743–750 (2000). Reveals the structural basis by which heparan sulphate promotes ligand-induced FGFR dimerization.
Chen, H. et al. A crystallographic snapshot of tyrosine trans-phosphorylation in action. Proc. Natl Acad. Sci. USA 105, 19660–19665 (2008).
Furdui, C. M., Lew, E. D., Schlessinger, J. & Anderson, K. S. Autophosphorylation of FGFR1 kinase is mediated by a sequential and precisely ordered reaction. Mol. Cell 21, 711–717 (2006).
Gotoh, N. Regulation of growth factor signaling by FRS2 family docking/scaffold adaptor proteins. Cancer Sci. 99, 1319–1325 (2008).
Carpenter, G. & Ji, Q. Phospholipase C-γ as a signal-transducing element. Exp. Cell Res. 253, 15–24 (1999).
Bottcher, R. T. & Niehrs, C. Fibroblast growth factor signaling during early vertebrate development. Endocr. Rev. 26, 63–77 (2005).
Thisse, B. & Thisse, C. Functions and regulations of fibroblast growth factor signaling during embryonic development. Dev. Biol. 287, 390–402 (2005).
Turner, N. & Grose, R. Fibroblast growth factor signalling: from development to cancer. Nature Rev. Cancer 10, 116–129 (2010).
Asada, M. et al. Glycosaminoglycan affinity of the complete fibroblast growth factor family. Biochim. Biophys. Acta 1790, 40–48 (2009).
Perrimon, N. & Bernfield, M. Specificities of heparan sulphate proteoglycans in developmental processes. Nature 404, 725–728 (2000).
Goetz, R. et al. Molecular insights into the Klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol. Cell. Biol. 27, 3417–3428 (2007). Reveals the structural basis for the endocrine mode of action of FGF19 subfamily ligands.
Rapraeger, A. C., Krufka, A. & Olwin, B. B. Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science 252, 1705–1708 (1991).
Yayon, A., Klagsbrun, M., Esko, J. D., Leder, P. & Ornitz, D. M. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 64, 841–848 (1991).
Ding, X. et al. βKlotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metab. 16, 387–393 (2012).
Kurosu, H. et al. Tissue-specific expression of βKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J. Biol. Chem. 282, 26687–26695 (2007).
Kurosu, H. et al. Regulation of fibroblast growth factor-23 signaling by Klotho. J. Biol. Chem. 281, 6120–6123 (2006).
Nakatani, T., Ohnishi, M. & Razzaque, M. S. Inactivation of klotho function induces hyperphosphatemia even in presence of high serum fibroblast growth factor 23 levels in a genetically engineered hypophosphatemic (Hyp) mouse model. FASEB J. 23, 3702–3711 (2009).
Ogawa, Y. et al. βKlotho is required for metabolic activity of fibroblast growth factor 21. Proc. Natl Acad. Sci. USA 104, 7432–7437 (2007).
Tomiyama, K. et al. Relevant use of Klotho in FGF19 subfamily signaling system in vivo. Proc. Natl Acad. Sci. USA 107, 1666–1671 (2010).
Urakawa, I. et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444, 770–774 (2006).
Dorey, K. & Amaya, E. FGF signalling: diverse roles during early vertebrate embryogenesis. Development 137, 3731–3742 (2010).
Hart, A. W., Baeza, N., Apelqvist, A. & Edlund, H. Attenuation of FGF signalling in mouse β-cells leads to diabetes. Nature 408, 864–868 (2000). Identifies a crucial role for FGF signalling in pancreatic β-cell function and glucose homeostasis in the adult.
Jonker, J. W. et al. A PPARγ–FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis. Nature 485, 391–394 (2012). Identifies a crucial role for FGF1 in the remodelling of adipose tissue in response to fluctuating nutrient availability.
Zhou, M. et al. Fibroblast growth factor 2 control of vascular tone. Nature Med. 4, 201–207 (1998).
Sakaue, H. et al. Requirement of fibroblast growth factor 10 in development of white adipose tissue. Genes Dev. 16, 908–912 (2002).
Potthoff, M. J., Kliewer, S. A. & Mangelsdorf, D. J. Endocrine fibroblast growth factors 15/19 and 21: from feast to famine. Genes Dev. 26, 312–324 (2012).
Quarles, L. D. Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. Nature Rev. Endocrinol. 8, 276–286 (2012).
Razzaque, M. S. The FGF23–Klotho axis: endocrine regulation of phosphate homeostasis. Nature Rev. Endocrinol. 5, 611–619 (2009).
Long, Y. C. & Kharitonenkov, A. Hormone-like fibroblast growth factors and metabolic regulation. Biochim. Biophys. Acta 1812, 791–795 (2011).
Beenken, A. & Mohammadi, M. The FGF family: biology, pathophysiology and therapy. Nature Rev. Drug Discov. 8, 235–253 (2009).
Wilkie, A. O. Bad bones, absent smell, selfish testes: the pleiotropic consequences of human FGF receptor mutations. Cytokine Growth Factor Rev. 16, 187–203 (2005).
Goetz, R. et al. Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23–FGFR–Klotho complex formation. Proc. Natl Acad. Sci. USA 107, 407–412 (2010).
Kalinina, J. et al. Homodimerization controls the fibroblast growth factor 9 subfamily's receptor binding and heparan sulfate-dependent diffusion in the extracellular matrix. Mol. Cell. Biol. 29, 4663–4678 (2009).
Olsen, S. K. et al. Structural basis by which alternative splicing modulates the organizer activity of FGF8 in the brain. Genes Dev. 20, 185–198 (2006). Identifies the molecular mechanism by which N-terminal splicing regulates the biological activity of FGF8 and provides structural evidence for ligand-induced differences in FGFR dimerization.
Plotnikov, A. N. et al. Crystal structure of fibroblast growth factor 9 reveals regions implicated in dimerization and autoinhibition. J. Biol. Chem. 276, 4322–4329 (2001).
Yeh, B. K. et al. Structural basis by which alternative splicing confers specificity in fibroblast growth factor receptors. Proc. Natl Acad. Sci. USA 100, 2266–2271 (2003). Reveals the molecular basis by which alternative splicing in the D3 domain of FGFR2 regulates the ligand-binding specificity of this receptor.
Gallagher, J. T. Heparan sulfate: growth control with a restricted sequence menu. J. Clin. Invest. 108, 357–361 (2001).
Chen, Y., Mohammadi, M. & Flanagan, J. G. Graded levels of FGF protein span the midbrain and can instruct graded induction and repression of neural mapping labels. Neuron 62, 773–780 (2009).
Harada, M. et al. FGF9 monomer–dimer equilibrium regulates extracellular matrix affinity and tissue diffusion. Nature Genet. 41, 289–298 (2009).
Makarenkova, H. P. et al. Differential interactions of FGFs with heparan sulfate control gradient formation and branching morphogenesis. Sci. Signal. 2, ra55 (2009).
Qu, X. et al. Lacrimal gland development and Fgf10–Fgfr2b signaling are controlled by 2-O- and 6-O-sulfated heparan sulfate. J. Biol. Chem. 286, 14435–14444 (2011). Demonstrates that a specific fine structure of the heparan sulphate produced by the cell responding to an FGF ligand is required for FGF signalling.
Qu, X. et al. Glycosaminoglycan-dependent restriction of FGF diffusion is necessary for lacrimal gland development. Development 139, 2730–2739 (2012). Demonstrates that the heparan sulphate produced by the cell secreting an FGF ligand mediates the formation of an FGF gradient in the extracellular matrix and that its fine structure is a crucial determinant in this process.
Murakami, H. et al. Elbow knee synostosis (Eks): a new mutation on mouse chromosome 14. Mamm. Genome 13, 341–344 (2002).
Crossley, P. H. & Martin, G. R. The mouse Fgf8 gene encodes a family of polypeptides and is expressed in regions that direct outgrowth and patterning in the developing embryo. Development 121, 439–451 (1995).
Gemel, J., Gorry, M., Ehrlich, G. D. & MacArthur, C. A. Structure and sequence of human FGF8. Genomics 35, 253–257 (1996).
MacArthur, C. A. et al. FGF-8 isoforms activate receptor splice forms that are expressed in mesenchymal regions of mouse development. Development 121, 3603–3613 (1995).
Xu, J., Lawshe, A., MacArthur, C. A. & Ornitz, D. M. Genomic structure, mapping, activity and expression of fibroblast growth factor 17. Mech. Dev. 83, 165–178 (1999).
Sato, T., Araki, I. & Nakamura, H. Inductive signal and tissue responsiveness defining the tectum and the cerebellum. Development 128, 2461–2469 (2001).
Lee, S. M., Danielian, P. S., Fritzsch, B. & McMahon, A. P. Evidence that FGF8 signalling from the midbrain-hindbrain junction regulates growth and polarity in the developing midbrain. Development 124, 959–969 (1997).
Liu, A., Losos, K. & Joyner, A. L. FGF8 can activate Gbx2 and transform regions of the rostral mouse brain into a hindbrain fate. Development 126, 4827–4838 (1999).
Christen, B. & Slack, J. M. FGF-8 is associated with anteroposterior patterning and limb regeneration in Xenopus. Dev. Biol. 192, 455–466 (1997).
Fletcher, R. B., Baker, J. C. & Harland, R. M. FGF8 spliceforms mediate early mesoderm and posterior neural tissue formation in Xenopus. Development 133, 1703–1714 (2006).
Falardeau, J. et al. Decreased FGF8 signaling causes deficiency of gonadotropin-releasing hormone in humans and mice. J. Clin. Invest. 118, 2822–2831 (2008). Implicates decreased FGF8 signalling in the deficiency of gonadotropin-releasing hormone that underlies idiopathic hypogonadotropic hypogonadism and presents an example for the role of N-terminal alternative splicing in regulating the biological activity of FGF8.
Shimada, T. et al. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 143, 3179–3182 (2002).
White, K. E. et al. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int. 60, 2079–2086 (2001).
Seidah, N. G. & Prat, A. The biology and therapeutic targeting of the proprotein convertases. Nature Rev. Drug Discov. 11, 367–383 (2012).
Gram Schjoldager, K. T. et al. A systematic study of site-specific GalNAc-type O-glycosylation modulating proprotein convertase processing. J. Biol. Chem. 286, 40122–40132 (2011).
White, K. E. et al. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nature Genet. 26, 345–348 (2000). Identifies FGF23 as a phosphaturic hormone and missense mutations at the proteolytic cleavage site of FGF23 as the cause for the renal phosphate wasting disease autosomal dominant hypophosphatemic rickets.
Frishberg, Y. et al. Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23. J. Bone Miner. Res. 22, 235–242 (2007).
Kato, K. et al. Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation. J. Biol. Chem. 281, 18370–18377 (2006).
Hsu, Y. R. et al. Human keratinocyte growth factor recombinantly expressed in Chinese hamster ovary cells: isolation of isoforms and characterization of post-translational modifications. Protein Expr. Purif. 12, 189–200 (1998).
Kim, G. Y. et al. HtrA1 is a novel antagonist controlling FGF signaling via cleavage of FGF8. Mol. Cell. Biol. 4 Sept 2012 (doi:10.1128/MCB.00872-12).
Avivi, A., Yayon, A. & Givol, D. A novel form of FGF receptor-3 using an alternative exon in the immunoglobulin domain III. FEBS Lett. 330, 249–252 (1993).
Chellaiah, A. T., McEwen, D. G., Werner, S., Xu, J. & Ornitz, D. M. Fibroblast growth factor receptor (FGFR) 3. Alternative splicing in immunoglobulin-like domain III creates a receptor highly specific for acidic FGF/FGF-1. J. Biol. Chem. 269, 11620–11627 (1994).
Johnson, D. E., Lu, J., Chen, H., Werner, S. & Williams, L. T. The human fibroblast growth factor receptor genes: a common structural arrangement underlies the mechanisms for generating receptor forms that differ in their third immunoglobulin domain. Mol. Cell. Biol. 11, 4627–4634 (1991).
Miki, T. et al. Determination of ligand-binding specificity by alternative splicing: two distinct growth factor receptors encoded by a single gene. Proc. Natl Acad. Sci. USA 89, 246–250 (1992).
Orr-Urtreger, A. et al. Developmental localization of the splicing alternatives of fibroblast growth factor receptor-2 (FGFR2). Dev. Biol. 158, 475–486 (1993).
Yan, G., Fukabori, Y., McBride, G., Nikolaropolous, S. & McKeehan, W. L. Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)–FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Mol. Cell. Biol. 13, 4513–4522 (1993).
Yayon, A. et al. A confined variable region confers ligand specificity on fibroblast growth factor receptors: implications for the origin of the immunoglobulin fold. EMBO J. 11, 1885–1890 (1992).
Wuechner, C., Nordqvist, A. C., Winterpacht, A., Zabel, B. & Schalling, M. Developmental expression of splicing variants of fibroblast growth factor receptor 3 (FGFR3) in mouse. Int. J. Dev. Biol. 40, 1185–1188 (1996).
Zhang, X. et al. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J. Biol. Chem. 281, 15694–15700 (2006).
Alarid, E. T. et al. Keratinocyte growth factor functions in epithelial induction during seminal vesicle development. Proc. Natl Acad. Sci. USA 91, 1074–1078 (1994).
Colvin, J. S., White, A. C., Pratt, S. J. & Ornitz, D. M. Lung hypoplasia and neonatal death in Fgf9-null mice identify this gene as an essential regulator of lung mesenchyme. Development 128, 2095–2106 (2001).
De Moerlooze, L. et al. An important role for the IIIb isoform of fibroblast growth factor receptor 2 (FGFR2) in mesenchymal–epithelial signalling during mouse organogenesis. Development 127, 483–492 (2000).
Min, H. et al. Fgf-10 is required for both limb and lung development and exhibits striking functional similarity to Drosophila branchless. Genes Dev. 12, 3156–3161 (1998).
Sekine, K. et al. Fgf10 is essential for limb and lung formation. Nature Genet. 21, 138–141 (1999).
Xu, X. et al. Fibroblast growth factor receptor 2 (FGFR2)-mediated reciprocal regulation loop between FGF8 and FGF10 is essential for limb induction. Development 125, 753–765 (1998). Provides genetic evidence for the crucial role of FGFR2 in bidirectional paracrine FGF signalling between the epithelium and the mesenchyme that initiates the outgrowth of limb buds.
Zhang, X. et al. Reciprocal epithelial–mesenchymal FGF signaling is required for cecal development. Development 133, 173–180 (2006).
Plotnikov, A. N., Hubbard, S. R., Schlessinger, J. & Mohammadi, M. Crystal structures of two FGF–FGFR complexes reveal the determinants of ligand-receptor specificity. Cell 101, 413–424 (2000).
Wang, F., Kan, M., Xu, J., Yan, G. & McKeehan, W. L. Ligand-specific structural domains in the fibroblast growth factor receptor. J. Biol. Chem. 270, 10222–10230 (1995).
Lajeunie, E. et al. FGFR2 mutations in Pfeiffer syndrome. Nature Genet. 9, 108 (1995).
Nagase, T., Nagase, M., Hirose, S. & Ohmori, K. Mutations in fibroblast growth factor receptor 2 gene and craniosynostotic syndromes in Japanese children. J. Craniofac. Surg. 9, 162–170 (1998).
Ibrahimi, O. A. et al. Biochemical analysis of pathogenic ligand-dependent FGFR2 mutations suggests distinct pathophysiological mechanisms for craniofacial and limb abnormalities. Hum. Mol. Genet. 13, 2313–2324 (2004).
Olsen, S. K. et al. Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity. Proc. Natl Acad. Sci. USA 101, 935–940 (2004).
Plotnikov, A. N., Schlessinger, J., Hubbard, S. R. & Mohammadi, M. Structural basis for FGF receptor dimerization and activation. Cell 98, 641–650 (1999).
Stauber, D. J., DiGabriele, A. D. & Hendrickson, W. A. Structural interactions of fibroblast growth factor receptor with its ligands. Proc. Natl Acad. Sci. USA 97, 49–54 (2000).
Goetz, R. et al. Conversion of a paracrine fibroblast growth factor into an endocrine fibroblast growth factor. J. Biol. Chem. 287, 29134–29146 (2012).
Ito, S., Fujimori, T., Hayashizaki, Y. & Nabeshima, Y. Identification of a novel mouse membrane-bound family 1 glycosidase-like protein, which carries an atypical active site structure. Biochim. Biophys. Acta 1576, 341–345 (2002).
Ito, S. et al. Molecular cloning and expression analyses of mouse βKlotho, which encodes a novel Klotho family protein. Mech. Dev. 98, 115–119 (2000).
Kuro-o, M. et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390, 45–51 (1997).
Yahata, K. et al. Molecular cloning and expression of a novel Klotho-related protein. J. Mol. Med. (Berl.) 78, 389–394 (2000).
Henrissat, B. A classification of glycosyl hydrolases based on amino acid sequence similarities. Biochem. J. 280, 309–316 (1991).
Henrissat, B. & Bairoch, A. New families in the classification of glycosyl hydrolases based on amino acid sequence similarities. Biochem. J. 293, 781–788 (1993).
Henrissat, B. & Bairoch, A. Updating the sequence-based classification of glycosyl hydrolases. Biochem. J. 316, 695–696 (1996).
Fon Tacer, K. et al. Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol. Endocrinol. 24, 2050–2064 (2010).
Goetz, R. et al. Klotho coreceptors inhibit signaling by paracrine fibroblast growth factor 8 subfamily ligands. Mol. Cell. Biol. 32, 1944–1954 (2012).
Kharitonenkov, A. et al. FGF-21/FGF-21 receptor interaction and activation is determined by βKlotho. J. Cell. Physiol. 215, 1–7 (2008).
Li, S. A. et al. Immunohistochemical localization of Klotho protein in brain, kidney, and reproductive organs of mice. Cell Struct. Funct. 29, 91–99 (2004).
Machado, M. F. et al. Regulation and action of fibroblast growth factor 17 in bovine follicles. J. Endocrinol. 202, 347–353 (2009).
Portela, V. M. et al. Expression and function of fibroblast growth factor 18 in the ovarian follicle in cattle. Biol. Reprod. 83, 339–346 (2010).
Gabrielsson, B. G. et al. Depot-specific expression of fibroblast growth factors in human adipose tissue. Obes. Res. 10, 608–616 (2002).
Jaskoll, T. et al. FGF10/FGFR2b signaling plays essential roles during in vivo embryonic submandibular salivary gland morphogenesis. BMC Dev. Biol. 5, 11 (2005).
Mailleux, A. A. et al. Role of FGF10/FGFR2b signaling during mammary gland development in the mouse embryo. Development 129, 53–60 (2002).
Qiao, J. et al. FGF-7 modulates ureteric bud growth and nephron number in the developing kidney. Development 126, 547–554 (1999).
Terauchi, A. et al. Distinct FGFs promote differentiation of excitatory and inhibitory synapses. Nature 465, 783–787 (2010).
Dutchak, P. A. et al. Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones. Cell 148, 556–567 (2012). Identifies FGF21 as a mediator of the metabolic actions of PPARγ and hence provides new insight into the mechanism of action of the thiazolidinedione class of antidiabetic drugs, which are PPARγ agonists.
Tontonoz, P. & Spiegelman, B. M. Fat and beyond: the diverse biology of PPARγ. Annu. Rev. Biochem. 77, 289–312 (2008).
Hotta, Y. et al. Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver. Endocrinology 150, 4625–4633 (2009).
Ming, A. Y. et al. Dynamics and distribution of Klothoβ (KLB) and fibroblast growth factor receptor-1 (FGFR1) in living cells reveal the fibroblast growth factor-21 (FGF21)-induced receptor complex. J. Biol. Chem. 287, 19997–20006 (2012).
Kouhara, H. et al. A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway. Cell 89, 693–702 (1997).
Lamothe, B. et al. The docking protein Gab1 is an essential component of an indirect mechanism for fibroblast growth factor stimulation of the phosphatidylinositol 3-kinase/Akt antiapoptotic pathway. Mol. Cell. Biol. 24, 5657–5666 (2004).
Brunet, A. et al. Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell 96, 857–868 (1999).
Datta, S. R. et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91, 231–241 (1997).
Hartwig, J. H. et al. MARCKS is an actin filament crosslinking protein regulated by protein kinase C and calcium-calmodulin. Nature 356, 618–622 (1992).
Li, H., Rao, A. & Hogan, P. G. Interaction of calcineurin with substrates and targeting proteins. Trends Cell Biol. 21, 91–103 (2011).
Ye, S. et al. Structural basis for interaction of FGF-1, FGF-2, and FGF-7 with different heparan sulfate motifs. Biochemistry 40, 14429–14439 (2001).
Acknowledgements
The authors thank J. Ma for help with preparing the structures. Studies on the structural basis of FGF signalling in the Mohammadi laboratory are funded by the U.S. National Institutes of Health grant DE13686.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Related links
Glossary
- Paracrine
-
Refers to a mode of signalling in which the cell responding to a signalling molecule is near the cell secreting the molecule.
- Endocrine
-
Refers to a mode of signalling in which the cell responding to a signalling molecule is far away from the cell secreting the molecule.
- Transphosphorylation
-
The process by which one kinase molecule in a kinase dimer phosphorylates the other (also referred to as autophosphorylation).
- Proteoglycans
-
Protein–glycan conjugates that consist of a core protein to which one or more glycosaminoglycan chains are attached.
- Morphogenesis
-
Process of cell movement during embryonic development that controls the size, shape and patterning of tissues and organs.
- β-trefoil
-
Portion of a protein that consists of 12 β-strands arranged into 3 similar sets of 4-stranded β-sheets.
- Epimerization
-
Process by which an epimer of a molecule is converted into its stereoisomeric counterpart.
- Submandibular gland
-
Gland located under the mandible bone that secretes saliva into the mouth.
- Elbow knee synostosis
-
(Eks). Mouse skeletal phenotype characterized by bone fusion at elbow and knee joints.
- Lacrimal gland
-
Gland of the eye that produces tear fluid to keep the eye lubricated.
- Idiopathic hypogonadotropic hypogonadism
-
Hereditary disorder characterized by the failure of sexual maturation and infertility due to deficiency of gonadotropin-releasing hormone.
- Renal phosphate wasting disease
-
Inherited or acquired condition characterized by excessive renal excretion of phosphate due to impaired tubular reabsorption.
- Hyperphosphatemia
-
Increase in blood phosphate levels above normal.
Rights and permissions
About this article
Cite this article
Goetz, R., Mohammadi, M. Exploring mechanisms of FGF signalling through the lens of structural biology. Nat Rev Mol Cell Biol 14, 166–180 (2013). https://doi.org/10.1038/nrm3528
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrm3528
This article is cited by
-
FGF23 and klotho at the intersection of kidney and cardiovascular disease
Nature Reviews Cardiology (2024)
-
Unveiling the molecular Hallmarks of Peyronie’s disease: a comprehensive narrative review
International Journal of Impotence Research (2024)
-
Fibroblast growth factor signaling in axons: from development to disease
Cell Communication and Signaling (2023)
-
Cellular senescence in skeletal disease: mechanisms and treatment
Cellular & Molecular Biology Letters (2023)
-
Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer
Scientific Reports (2023)